Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Cut to $25.00

Zentalis Pharmaceuticals (NASDAQ:ZNTLFree Report) had its price objective cut by Oppenheimer from $50.00 to $25.00 in a research report released on Tuesday morning, Benzinga reports. They currently have an outperform rating on the stock.

Several other research analysts also recently issued reports on ZNTL. Stifel Nicolaus lowered their price target on shares of Zentalis Pharmaceuticals from $32.00 to $10.00 and set a buy rating for the company in a report on Tuesday. Wells Fargo & Company cut shares of Zentalis Pharmaceuticals from an overweight rating to an equal weight rating and reduced their price objective for the stock from $29.00 to $9.00 in a research note on Tuesday. HC Wainwright reduced their price objective on shares of Zentalis Pharmaceuticals from $40.00 to $20.00 and set a buy rating on the stock in a research note on Tuesday. Finally, Wedbush cut shares of Zentalis Pharmaceuticals from a neutral rating to an underperform rating and reduced their price objective for the stock from $15.00 to $4.00 in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of Hold and an average target price of $11.33.

Read Our Latest Analysis on Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL opened at $4.75 on Tuesday. The firm has a 50 day simple moving average of $11.16 and a two-hundred day simple moving average of $12.97. The company has a market cap of $337.39 million, a P/E ratio of -1.42 and a beta of 1.83. Zentalis Pharmaceuticals has a one year low of $3.93 and a one year high of $29.63.

Zentalis Pharmaceuticals (NASDAQ:ZNTLGet Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.91. The company had revenue of $40.56 million for the quarter, compared to analyst estimates of $35.00 million. During the same quarter last year, the company posted ($1.07) earnings per share. On average, analysts expect that Zentalis Pharmaceuticals will post -2.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, CFO Cam Gallagher sold 9,597 shares of the stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $11.98, for a total transaction of $114,972.06. Following the completion of the sale, the chief financial officer now directly owns 633,680 shares in the company, valued at approximately $7,591,486.40. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Diana Hausman sold 3,356 shares of the firm’s stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $12.62, for a total value of $42,352.72. Following the completion of the sale, the insider now directly owns 373,876 shares in the company, valued at approximately $4,718,315.12. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Cam Gallagher sold 9,597 shares of the firm’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $11.98, for a total value of $114,972.06. Following the completion of the sale, the chief financial officer now owns 633,680 shares of the company’s stock, valued at $7,591,486.40. The disclosure for this sale can be found here. Company insiders own 6.10% of the company’s stock.

Institutional Trading of Zentalis Pharmaceuticals

Several large investors have recently made changes to their positions in ZNTL. Eventide Asset Management LLC grew its stake in shares of Zentalis Pharmaceuticals by 47.9% in the 4th quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock valued at $175,134,000 after buying an additional 3,745,936 shares during the period. Decheng Capital LLC acquired a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter valued at about $31,809,000. Price T Rowe Associates Inc. MD grew its stake in shares of Zentalis Pharmaceuticals by 20.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock valued at $54,999,000 after buying an additional 585,644 shares during the period. Vanguard Group Inc. grew its stake in shares of Zentalis Pharmaceuticals by 6.2% in the 3rd quarter. Vanguard Group Inc. now owns 5,236,663 shares of the company’s stock valued at $105,047,000 after buying an additional 307,490 shares during the period. Finally, Federated Hermes Inc. grew its stake in shares of Zentalis Pharmaceuticals by 10.9% in the 4th quarter. Federated Hermes Inc. now owns 2,160,565 shares of the company’s stock valued at $32,733,000 after buying an additional 212,872 shares during the period.

Zentalis Pharmaceuticals Company Profile

(Get Free Report)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

Featured Stories

Analyst Recommendations for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.